ESMO 2018 | Challenges in the treatment of mTNBC

Metastatic triple negative breast cancer (mTNBC) remains one of the most aggressive subtypes of breast cancer. In this video, Peter Schmid, MD, FRCP, PhD, of the Barts Cancer Institute, London, UK, describes the relatively poor treatment outcomes for these patients, attributing these outcomes to resistance from chemotherapy, and the heterogeneous nature of the cancer. Speaking at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Prof. Schmid further highlights the importance of implementing targeted therapies for mTNBC to improve survival outcomes.